Swiss bank UBS renews its recommendation towards the Israeli pharmaceutical laboratory Teva Pharmaceutical Industries Ltd. (NYSE: Suits you; TASE: Suits you) to buy from neutral. UBs also raised its price target for Teva from $11 to $13. The company is currently trading on Wall Street down 0.86% at $9.80 per share, representing a market capitalization of $11.006 billion.
RELATED ARTICLES
UBS wrote: « Teva is uniquely positioned to undertake a significant transition to a more brand-centric company, which we believe can drive stock market outperformance. »
The analysts added: “Going forward, we expect more focus to be placed on attractive branded assets, where investors can participate in launch acceleration and pipeline de-risking catalysts. »
Published by Globes, Israel Business News – fr.globes.co.il – November 28, 2023.
© Copyright of Globes Publisher Itonut (1983) Ltd., 2023.
